Gerben R. Borst

Early Cellular Responses to Tumor Treating Fields in Glioblastoma

Claire O’Leary, Gabriella Forte, Paul L G Slangen, Caroline van Heijningen et autres

Abstract Background Tumor Treating Fields (TTFields) are a clinically validated therapy that has contributed to improved survival outcomes in glioblastoma patients. A deeper understanding of the underlying cellular mechanisms of TTFields could further advance therapeutic strategies. Here we explore the early impact …

gb, nl (code pays fourni par la source)

DeepPathway: predicting pathway expression from histopathology images

Muhammad Ahsan, Karen Piper Hanley, Martin Fergie, Claire O’Leary et autres

MOTIVATION: Spatial transcriptomics (ST) technologies provide spatially resolved gene expression along with image data, allowing the integrative analysis of complex tissue microenvironment. Despite their potential, the widespread adoption of ST remains limited due to high costs, and methodological challenges in data acquisition. …

gb (code pays fourni par la source)

CTNI-20. NEOADJUVANT RADIOTHERAPY IN GLIOBLASTOMA IDH-WILDTYPE: INTERIM RESULTS FROM THE POBIG (PREOPERATIVE BRAIN IRRADIATION IN GLIOBLASTOMA) STUDY

Gerben R. Borst, Federico Roncaroli, Shefali Parikh, Mueez Waqar et autres

Abstract Glioblastoma IDH-wildtype is a highly infiltrative and aggressive brain tumour, making complete surgical resection unachievable. Preclinical evidence suggests that surgical manipulation may contribute to tumour recurrence by stimulating the proliferative and migratory potential of the tumour. Neoadjuvant approaches, treating the tumour …

gb, nl (code pays fourni par la source)

P02.09.B SURGICAL RESECTION OF GLIOBLASTOMA INDUCES IMMUNOSUPPRESSION

J Reveilles, Alberto Ballestín, Cathy Pichol-Thievend, Amandine Thomas et autres

Abstract BACKGROUND Glioblastoma (GB) is one of the deadliest cancers, recurring at a rate of 90%, despite a high standard of care composed of gross total surgery, fractioned and concomitant chemoradiation, and adjuvant chemotherapy. Moreover, numerous immunotherapies have not succeeded in enhancing …

fr, gb, de, lu, us, nl (code pays fourni par la source)

OS05.7.A NEUROSURGERY IN GLIOBLASTOMA INDUCES CELL PLASTICITY, THERAPY RESISTANCE AND IMMUNOSUPPRESSION BY ISCHEMIC HYPOXIA

Alberto Ballestín, J Reveilles, Valentino Ribecco, Cathy Pichol-Thievend et autres

Abstract BACKGROUND Glioblastoma (GBM) is the most lethal and prevalent malignant brain tumor, with patients facing a median survival of 8 months and only 6.9% reaching five-year survival. The standard of care includes surgical resection of the tumor, radiotherapy, and concomitant chemotherapy …

fr, de, lu, us, nl (code pays fourni par la source)

P09.16.A TREATMENT OF BRAIN RADIONECROSIS: A SURVEY OF PROVISION OF CARE AND ACCESS TO BEVACIZUMAB IN THE UNITED KINGDOM

S. Kingdon, Shefali Parikh, Stephen Robinson, Emma Lim et autres

Abstract BACKGROUND Radiation necrosis (RN) in the brain, is a treatment-related effect of cranial radiotherapy that can lead to significant neurological symptoms. In symptomatic cases, steroids are often used first line. However, prolonged steroid use can lead to significant toxicity. There is …

gb (code pays fourni par la source)

Dose dependency of MRI changes following pre-operative radiotherapy in glioblastoma; volumetric, ASL and APT changes

Aisling Fothergill, Mueez Waqar, Alina Sovetkina, David Higgins et autres

Motivation: Prognosis for people with glioblastoma remains poor, pre-operative radiotherapy may improve outcome. Goal(s): Determine early changes after pre-operative radiotherapy using T1w+contrast, FLAIR, Arterial Spin Labelling (ASL) and Amide Proton Transfer-weighted (APTw) MRI to better understand early impact of radiotherapy on tumours. …

Staged Gamma Knife radiosurgery for large brain metastases: local control and the influence of systemic treatment

R G Huisman, Petra van Schie, Laura G. Merckel, T. Wiersma et autres

BACKGROUND AND PURPOSE: Staged Gamma Knife radiosurgery (SGKRS) delivers high-dose radiotherapy to large brain metastases (BM) in two or three fractions with a time interval of several weeks. Various systemic treatments have also demonstrated favorable intracranial responses. Therefore, the outcome of patients …

nl, gb (code pays fourni par la source)

IMPLEMENTING ROUTINE ELECTRONIC PATIENT-REPORTED OUTCOME MEASURES (EPROMS) FOR PATIENTS WITH PRIMARY TUMOURS OF THE CENTRAL NERVOUS SYSTEM

Julie Emerson, Thitikorn Nuamek, Lindsay Sudell, Gerben R. Borst et autres

Abstract AIMS Electronic patient-reported outcome measures (ePROMs) are online questionnaires designed to collect patients’ self-reported information about their health. While the benefits of ePROMs in patient care are well-documented, their integration into routine clinical care remains limited, particularly for patients with central …

gb (code pays fourni par la source)

DEVELOPING A NURSE LED CLINIC TO DELIVER VORASIDINIB – PRACTICALITIES, PATIENTS AND OUTCOMES

Lisa Withington, Jennifer Bristow, Jocelyn Puzylo, Karan Patel et autres

Abstract AIMS The aim to establish a nurse-led service to facilitate patient access to Vorasidenib via the Managed Access Pro- gramme (MAP) independent of consultants’ clinic capacity; to define and pilot clinical management protocols; to quantify and evaluate the first cohort of …

gb (code pays fourni par la source)

708P Initial experience with the routine use of electronic patient-reported outcome measures for patients with glioblastoma

Juen Kiem Tan, Thitikorn Nuamek, Karan Patel, J. Emerson et autres

gb, hk (code pays fourni par la source)

Targeting the glioblastoma resection margin with locoregional nanotechnologies

Thomas Kisby, Gerben R. Borst, David Coope, Kostas Kostarelos

gb, es (code pays fourni par la source)